141080

LigaChem Biosciences is a biotechnology company focused on the research and development of novel therapeutics, primarily in the areas of antibody-drug conjugates (ADCs), synthetic small molecules, and immunotherapy. The company develops its proprietary ADC platform technology, ConjuALL, which utilizes unique linkers and payloads to target cancer cells. Its pipeline includes multiple ADC candidates such as LCB14 (HER2), LCB71 (ROR1), LCB84 (TROP2), and LCB97 (L1CAM), which are in various stages of clinical trials or have been licensed out to global partners including Janssen, Ono Pharma, CStone, and Iksuda. In addition to its R&D business, the company operates a medical business segment that supplies medical devices and consumables to hospitals in the Seoul metropolitan area. LigaChem Biosciences collaborates with international pharmaceutical companies through technology transfer, co-development, and licensing agreements to advance its drug candidates toward commercialization.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage ligachembio.com
Sector Healthcare IR page ligachembio.com
Tags
antibody-drug conjugates, immunotherapy, synthetic small molecules, oncology, antibiotics, medical devices, medical consumables, technology transfer, drug discovery, ConjuALL, LCB14, LCB71, LCB84, LCB97, LCB02A, LCB43, Caxmotabart Entudotin, CS5001, Iksuda, Janssen, Ono Pharma, CStone, Fosun Pharma, AntibodyChem Biosciences, Bascan Biopharmaceuticals
Press page —

Metrics

Valuation  
Market cap ₩ 3.152T
Market cap (USD) $ 2.32B
P/E -17.61
PEG —
P/BV 7.88
P/S 31.91
P/OCF -16.45
P/FCF -16.20
Dividend yield —
Turnover / mcap —
Returns  
ROE -16.3%
ROI -18.0%
ROIC -15.7%
Profit margin -64.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -69.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 141.553B — — — — 49.394B 57.5B 25.24B 22.057B 16.655B 1.788B 870.054M 839.825M
Net profit -91.552B 7.8B -73.704B -45.092B -23.391B -6.986B 13.586B -25.77B -12.934B -14.725B -8.237B -8.686B -5.835B
Free cash flow -127.582B 75.849B -63.555B -11.3B -60.358B -18.508B 20.743B -16.515B -10.412B -17.281B -9.145B -8.173B -7.314B

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 12.6B 15.5B 17.7B 11.1B 20.6B 22.5B 12.8B 14.8B 13.7B 11.8B
↳ YoY growth +36.7% +23.6% +13.8% -37.1% +85.0% +9.2% -43.1% +15.9% -7.4% -14.3%
↳ 5y CAGR +100.2% +172.2% +17.5% +12.3% -3.8% -3.5% +4.3% -10.6%
Borrowings, current (KRW) 6.17B 6.7B — 0.00 — 2.7B 11.8B 11.8B 0.00 0.00
Borrowings, non-current (KRW) 7.85B 8.52B 0.00 1.9B 3.61B 9.15B 0.00 0.00 — —
Bonds payable (KRW) 14B 15.2B — 0.00 — — — — — —
Lease liabilities (KRW) — — 0.00 285M 375M 422M 402M 797M 820M 2.75B
Cash and deposits (KRW) 2.97B 8.62B 10.2B 66.9B 54.6B 140B 118B 63.1B 129B 98.6B
Intangible assets (KRW) 26.8B — — — — 8.6B 7.89B 6.9B 8.44B 104B
Net debt (borrowings + leases - cash) (KRW) 4.89B 6.6B -10.2B -65B -50.7B -128B -106B -50.4B -128B -95.9B
Cash flow detail
Operating cash flow (KRW) -13B -8.21B -12.8B 24.1B -14.9B -42B -7.14B -62.2B 78.5B -125B
Purchases of property, plant and equipment (KRW) -4.24B -2.2B -3.76B -3.37B -3.61B -18.3B -4.16B -1.32B -2.63B -3.05B
Purchases of intangible assets (KRW) — -342M -213M -121M -480M -294M -608M -883M -3.07B -2.99B
Share buybacks (cash effect) (KRW) — — — — — 0.00 0.00 -4.88B -20B -7B
Interest paid (cash effect) (KRW) -307M -119M -93.6M 0.00 -37.1M -51.9M -288M -499M -547M -468M
Income taxes paid (cash effect) (KRW) -37.8M -14.5M -66.6M -504M 37.7M -82.1M -386M -1.09B -5.94B -8.52B
Free cash flow (OCF - PPE - intangibles) (KRW) -17.3B -10.8B -16.7B 20.6B -19B -60.7B -11.9B -64.4B 72.8B -131B
Income detail
Research and development expense (KRW) — — — — — — — 79.6B 113B 217B
Total comprehensive income (KRW) -14.8B -12.8B -25.8B 9.8B -4.16B -24B -45.7B -74.2B 6.47B -71.4B
Comprehensive income to owners (KRW) -14.8B -85.4M -25.5B 10.9B — — — -74.2B 6.47B -55.2B
Reported Mar 29, 2019 Mar 29, 2019 May 31, 2021 May 31, 2021 May 31, 2021 Mar 21, 2024 Mar 21, 2024 Mar 23, 2026 Mar 23, 2026 Mar 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

분기보고서 (2026.09) Bull 2 Bear 5 Results
기업설명회(IR)개최 Bull 0 Bear 0 Routine
Additional Listing(주식매수선택권행사) Bull 0 Bear 0 Routine

Prompts

LCB (ticker 141080), listed in South Korea.

ETFs Holding LCB

ETF Weight in ETF Shares Market value As of
DFSE 0.01% 731 $ 34.724K Nov 12, 2026
DFAE 0.00% 8,029 $ 381.399K Nov 12, 2026
DEXC 0.00% 171 $ 8,122.97 Nov 12, 2026
DFEM 0.00% 1,742 $ 82.75K Nov 12, 2026
AVEM 0.00% 2,616 $ 106.302K Nov 16, 2026
AVXC 0.00% 40 $ 1,625.42 Nov 16, 2026